http://bmj.com/cgi/content/full/324/7341/808/a
BMJ 2002;324:808 ( 6 April )
News
WHO links long term pill use to cervical cancer
Owen Dyer, London
A study carried out by the World Health Organization has produced the first
compelling evidence of a long suspected link between the
contraceptive pill and cervical cancer. The research, carried out by
the WHO's International Agency for Research on Cancer, found that
prolonged use of the oral contraceptive pill increased the risk of
cervical cancer up to fourfold, but only in women who carry the human
papillomavirus (HPV).
The agency's Multicentric Cervical Cancer Study Group reviewed eight studies
from Thailand, the Philippines, Morocco, Brazil, Peru, Paraguay,
Colombia, and Spain. Their results are published in last week's
Lancet (2002;359:1085-92). Women
who had taken the pill for 5-9 years were nearly three times more
likely than non-users to develop cervical cancer. Women who had taken
the pill for more than 10 years were four times more likely than
non-users to develop the disease. These risks did not vary with time
since first or last use, or by age at first use.
The study considered only women who were infected with HPV, because the
authors took the generally accepted view that the virus is "probably
a prerequisite for the development of the disease." Over 99% of women
in Britain in whom cervical cancer is diagnosed test positive for DNA
of HPV, an infection that affects a third of all women in their
twenties.
Another study by the same team, also in last week's Lancet
(2002;359:1093-101), confirmed the
widespread belief that multiple pregnancies are another risk factor
for cervical cancer. Women who tested positive for HPV and who had
had seven or more full term pregnancies were 3.8 times more likely to
develop the disease than infected nulliparous women.
"These factors appear to act as independent multipliers of risk," said Silvia
Franceschi, one of the studies' authors. HPV positive women who had
had more than five full term pregnancies and had taken the pill for
more than five years ran nearly 12 times the risk of cervical cancer
as HPV positive nulliparous women who had never taken the
pill.
"We don't have data on the types of pill being used, and it is possible they
were at higher doses than would be typical in Europe today," said Dr
Franceschi. "Some of the original studies dated from the late 1980s.
But from other studies we would expect a similar effect from
progesterone based preparations."
Cervical cancer is the most common cancer among women in many developing
countries. The overall lifetime risk is about 5% in parts of Africa,
India, and Latin America, compared with 1% in Europe and North
America. Yet HPV infection is extremely common throughout the world.
In the United Kingdom the virus is present in perhaps a third of all
women in their twenties.
In British women about 3000 cases of cervical cancer are diagnosed each year,
and 1300 women die from it. Both the incidence and mortality have
fallen considerably since the introduction of the Papanicolaou smear
test.
The Family Planning Association sought to allay fears about using the pill.
"The overall likelihood of getting cervical cancer in the UK is low,
whether you use the pill for a long time or not," said a spokeswoman.
"The benefits of using oral contraception outweigh the risks for the
vast majority of women. The pill reduces the risk of cancer of the
ovaries and of the womb."
Professor Gordon McVie, director of Cancer Research UK, also urged women not
to worry unduly. "It is important they attend their screening
appointments, which will pick up any changes long before they develop
into cancer."
© BMJ 2002
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.